One To Watch

Viridian Therapeutics

A clinical-stage biotechnology company singularly focused on thyroid eye disease, with a BLA under FDA Priority Review for veligrotug and a subcutaneous follow-on already in pivotal Phase III trials.

Company Overview

A clinical-stage biotechnology company singularly focused on thyroid eye disease, with a BLA under FDA Priority Review for veligrotug and a subcutaneous follow-on already in pivotal Phase III trials. Viridian Therapeutics has built its entire pipeline around inhibition of the insulin-like growth factor-1 receptor (IGF-1R), the validated but underexploited pathway driving TED pathology. The company is pursuing a two-asset strategy: an intravenous first-generation product approaching potential approval, and a subcutaneous next-generation molecule that, if it clears its trials, could reshape the treatment standard again within two years.

Headquarters and Global Presence

Viridian is headquartered in Boulder, Colorado. Its pivotal trials — THRIVE, THRIVE-2, REVEAL-1, and REVEAL-2 — are global studies, reflecting an international commercial ambition that goes well beyond the US market.

Founding and History

Viridian was founded to address a clear gap in rare autoimmune eye disease, where validated biology had not been fully exploited. The company went public on Nasdaq and raised a $175 million underwritten public offering in June 2024, comprising common stock and Series B preferred stock, to fund its pivotal program and pre-commercial buildout. Positive Phase III topline data from the THRIVE trial were reported in September 2024, and the BLA for veligrotug was accepted by the FDA under Priority Review in December 2025.

Therapy Areas and Focus

Viridian's sole therapeutic focus is thyroid eye disease, a disfiguring and potentially vision-threatening autoimmune condition in which orbital tissue inflammation causes proptosis, diplopia, and corneal exposure. The condition affects patients with Graves' disease and carries a significant burden, including facial disfigurement and psychological distress, yet the approved treatment landscape remains narrow. Viridian's concentration on TED is a deliberate bet that deep domain focus — rather than a diversified rare-disease portfolio — yields better clinical and commercial execution.

Technology Platforms and Modalities

Viridian's platform is built on full antagonism of IGF-1R, a receptor whose crosstalk with TSH receptor signaling drives the orbital fibroblast activation that characterizes TED. Both veligrotug and VRDN-003 are monoclonal antibodies against IGF-1R, but differ critically in their route of administration: intravenous versus subcutaneous. The subcutaneous format matters commercially — it removes the requirement for infusion center visits, opens up community endocrinology settings, and gives patients a far simpler treatment experience. Achieving best-in-class subcutaneous delivery with equivalent or superior efficacy is the company's defining technical ambition.

Key Pipeline and Programs

Veligrotug (VRDN-001) is a full-antagonist intravenous monoclonal antibody targeting IGF-1R for the treatment of TED. Its pivotal program comprised two global Phase III trials: THRIVE, conducted in active TED, and THRIVE-2, conducted in chronic TED. Both met their primary and all secondary endpoints, with positive long-term durability data, establishing the asset's clinical profile across the TED disease spectrum. The BLA was accepted by the FDA in December 2025 under Priority Review; veligrotug also carries Breakthrough Therapy Designation for TED. Commercial manufacturing has been secured through a five-year supply agreement with WuXi Biologics, with Viridian retaining the right to use alternate suppliers.

VRDN-003 is Viridian's subcutaneous IGF-1R antibody, designed as a potential best-in-class follow-on to veligrotug. It is currently in two global Phase III pivotal trials: REVEAL-1, enrolling patients with active TED, and REVEAL-2, enrolling chronic TED. Topline data from both REVEAL trials are expected in the first half of 2026, with a BLA submission planned by the end of 2026. If successful, VRDN-003 would put Viridian in the rare position of having two approved therapies in the same rare indication within a short window — a dynamic that could accelerate market penetration and complicate competitive entry.

Recent Developments

In September 2024, Viridian reported positive topline data from the Phase III THRIVE trial of veligrotug, confirming activity in active TED across primary and secondary endpoints. The FDA accepted the BLA for veligrotug under Priority Review in December 2025, a material regulatory milestone that puts potential approval in view. In parallel, Viridian signed a commercial manufacturing services agreement with WuXi Biologics covering drug substance and drug product supply for veligrotug, on an initial five-year auto-renewing term, positioning the company for commercial launch readiness. REVEAL-1 and REVEAL-2 topline data for VRDN-003 remain the next major catalysts, expected in the first half of 2026.

Key Personnel

Steven Mahoney serves as President and Chief Executive Officer, leading the company through its BLA review and pre-commercial stage. The executive team is supported by seasoned clinical and regulatory leadership whose oversight delivered two successful Phase III programs across the THRIVE studies. Full senior team details are available at the company's investor relations site.

Strategic Partnerships

Viridian's most significant operational partnership is with WuXi Biologics, covering long-term commercial manufacturing of veligrotug drug substance and drug product under a non-exclusive, five-year auto-renewing agreement. The non-exclusivity clause preserves Viridian's supply chain flexibility. Beyond manufacturing, the company has pursued an independent commercialization path, with no licensing deal or co-promotion partner disclosed for the US market.

FAQ Section

Teprotumumab, developed by Horizon Therapeutics, established IGF-1R inhibition as the dominant mechanism in TED and built a substantial commercial franchise. Viridian is directly challenging that position with veligrotug on efficacy and tolerability grounds, while its subcutaneous VRDN-003 offers a structurally different patient experience than Tepezza's infusion regimen. Two approved agents from a single sponsor — if VRDN-003 clears its trials — would give Viridian unusual pricing and access leverage in a narrow indication.

In TED, aberrant signaling between IGF-1R and the TSH receptor on orbital fibroblasts drives the inflammation and tissue remodeling that causes proptosis and diplopia. IGF-1R and TSHR form a physical complex, meaning IGF-1R blockade interrupts a core node of TED pathophysiology rather than a downstream effector. Teprotumumab's commercial success validated the target clinically; Viridian is betting it can improve on the first-generation execution with full antagonism and a more convenient format.

The key differentiation is route of administration: VRDN-003 is designed for subcutaneous delivery, eliminating the need for intravenous infusion center visits required by veligrotug and teprotumumab alike. A self-administered or office-based subcutaneous injection broadens the prescriber base beyond infusion-capable centers, potentially into community endocrinology and ophthalmology practices. Whether the subcutaneous format preserves the efficacy profile of intravenous IGF-1R blockade is the central clinical question the REVEAL trials are designed to answer.

The FDA accepted Viridian's BLA for veligrotug in December 2025 and placed it under Priority Review, reflecting the unmet need in TED. Veligrotug also holds Breakthrough Therapy Designation for this indication. The application is supported by positive Phase III data from both THRIVE (active TED) and THRIVE-2 (chronic TED), both of which met primary and all secondary endpoints with favorable durability data. Commercial supply arrangements with WuXi Biologics are already in place in anticipation of a potential approval decision.

Viridian's current disclosed pipeline is entirely focused on TED, with no publicly announced programs in adjacent indications. The company's strategic logic has been depth over breadth — executing two pivotal programs and a BLA filing in a single rare disease rather than spreading resources across multiple areas. Whether IGF-1R biology could be extended to other autoimmune or fibrotic conditions has not been publicly signaled as a near-term priority.

Viridian is at a late-stage inflection point: veligrotug is under FDA Priority Review following a successful Phase III program, and VRDN-003 is in pivotal Phase III with topline data expected in the first half of 2026. A BLA submission for VRDN-003 is targeted by end of 2026, which would place it on a potential approval timeline in 2027. The company raised $175 million in a public offering in June 2024 to fund this runway, and pre-commercial manufacturing infrastructure is being built ahead of a veligrotug launch decision.

The principal watchpoints for Viridian over the next 12-18 months are:

FDA action on the veligrotug BLA under Priority Review — the single most material near-term event for the company's valuation and commercial trajectory.
REVEAL-1 and REVEAL-2 topline data for VRDN-003, expected first half 2026 — success would confirm a subcutaneous franchise; failure would remove the follow-on story entirely.
Competitive response from the Amgen/Horizon portfolio — Tepezza's incumbent position means Viridian faces a well-resourced commercial adversary on launch.
WuXi Biologics supply chain exposure — the manufacturing agreement is non-exclusive, but any disruption tied to geopolitical scrutiny of WuXi adds execution risk ahead of a launch.
BLA submission timing for VRDN-003 by end 2026 — delays could compress the window between the two products and dilute the portfolio narrative.

Want to Update your Company's Profile?